Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2018 Aug;48(8):1063-1067.
doi: 10.1111/cea.13166. Epub 2018 Jun 4.

Nasopharyngeal CCL5 in infants with severe bronchiolitis and risk of recurrent wheezing: A multi-center prospective cohort study

K Hasegawa  1 , P A Piedra  2 , C S Bauer  3 , J C Celedón  4 , J M Mansbach  5 , J M Spergel  6 , J A Espinola  1 , C A Camargo Jr  1 ; MARC-35 Investigators
Collaborators, Affiliations
Multicenter Study

Nasopharyngeal CCL5 in infants with severe bronchiolitis and risk of recurrent wheezing: A multi-center prospective cohort study

K Hasegawa et al. Clin Exp Allergy. 2018 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: Dr. Piedra has provided bronchiolitis-related consultation for Gilead, Novavax, and Regeneron. Dr. Spergel has provided consultation for Dannone, DBV Technologies, Pfizer, and Regeneron. The other authors have no financial relationships relevant to this article to disclose.

Figures

Figure 1
Figure 1. Proportion of patients with solo respiratory syncytial virus (RSV) infection who remained recurrent wheezing-free over a 36-month period
Among infants with solo RSV infection, the risks of developing recurrent wheezing were significantly higher in those with intermediate CCL5 (adjusted HR, 1.57; 95%CI, 1.06–2.31; P=0.02) and those with high CCL5 (adjusted HR, 1.56; 95%CI, 1.04–2.32; P=0.03), compared to infants with low CCL5 levels. The number at risk indicates the number of patients at risk for developing recurrent wheeze at each age. The numbers decrease with age as patients who develop the outcome are censored in the survival analysis. As requested, we have added this information to the Figure Legend section.
See this image and copyright information in PMC

References

    1. Hasegawa K, Mansbach JM, Camargo CA., Jr Infectious pathogens and bronchiolitis outcomes. Exp Rev Ant Infect Ther. 2014;12(7):817–28. - PubMed
    1. Bacharier LB, Cohen R, Schweiger T, Yin-Declue H, Christie C, Zheng J, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012;130(1):91–100. e3. - PMC - PubMed
    1. Hasegawa K, Mansbach JM, Ajami NJ, Espinola JA, Henke DM, Petrosino JF, et al. Association of nasopharyngeal microbiota profiles with bronchiolitis severity in infants hospitalized for bronchiolitis. Eur Respir J. 2016;48:1329–39. - PMC - PubMed
    1. Ralston SL, Lieberthal AS, Meissner HC, Alverson BK, Baley JE, Gadomski AM, et al. Clinical practice guideline: the diagnosis, management, and prevention of bronchiolitis. Pediatrics. 2014;134(5):e1474–502. - PubMed
    1. US Department of Health and Human Services. National Asthma Education and Prevention Program: Expert Panel Report 3 (EPR 3): Guidelines for the Diagnosis and Management of Asthma (NIH Publication 08-4051) Bethesda, MD: National Institutes of Health; 2007.

LinkOut - more resources